InspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026
InspireMD Announces Pricing of $37.5 Million Public Offering
InspireMD (NSPR) Q3 2026 Earnings Call Transcript
InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens US ...
InspireMD Announces Proposed Public Offering
InspireMD Reports Third Quarter 2026 Financial Results
InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures
Update: InspireMD Q3 Adj. EPS $(0.11) Beats $(0.15) Estimate, Sales $2.242M Beat $1.996M Estimate
InspireMD Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $2.242M Beat $1.996M Estimate. Cash and Equivalents $19.246M
InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results
InspireMD to Announce Third Quarter 2026 Financial Results
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
Full Transcript: InspireMD Q2 2026 Earnings Call
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know
InspireMD Inc (NSPR) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges While ...
InspireMD, Inc. Q2 2026 Earnings Call Summary
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
InspireMD Reports Second Quarter 2026 Financial Results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.